ReP USP - Resultado da busca

Artigo de periodico-carta/editorial
ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia (2024)
Silva, Jean Carlos Lipreri da ; Silva, Juan Luiz Coelho da ; Vicari, Hugo Passos ; Lima, Keli Cristina de ; Rego, Eduardo Magalhães ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: Hematology, Transfusion and Cell Therapy. Unidades: FM, FMRP, ICB
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, MEDULA ÓSSEA, CÉLULAS SANGUÍNEAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Jean Carlos Lipreri da et al. ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2023.06.004. Acesso em: 18 nov. 2024. , 2024
APA
Silva, J. C. L. da, Silva, J. L. C. da, Vicari, H. P., Lima, K. C. de, Rego, E. M., Traina, F., & Machado Neto, J. A. (2024). ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.htct.2023.06.004
NLM
Silva JCL da, Silva JLC da, Vicari HP, Lima KC de, Rego EM, Traina F, Machado Neto JA. ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2024 ; 46( 1): 105-106.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.htct.2023.06.004
Vancouver
Silva JCL da, Silva JLC da, Vicari HP, Lima KC de, Rego EM, Traina F, Machado Neto JA. ARHGAP6 transcript levels are associated with molecular risk and impact survival outcomes in acute myeloid leukemia [Internet]. Hematology, Transfusion and Cell Therapy. 2024 ; 46( 1): 105-106.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.htct.2023.06.004
Artigo de periodico
Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors (2023)
Melo, Manuela Albuquerque de ; Macedo, Brunno Gilberto Santos ; Fonseca, Natasha Peixoto ; Scheucher, Priscila Santos ; Martins, Diego Antonio Pereira ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: Blood. Conference titles: 65th ASH Annual Meeting Abstracts. Unidades: FMRP, ICB
Subjects: FARMACOLOGIA, HEMATOLOGIA, CÉLULAS MIELOIDES, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MELO, Manuela Albuquerque de et al. Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors. Blood, v. 142, n. Supl. 1, p. 5752, 2023Tradução . . Disponível em: https://doi.org/10.1182/blood-2023-190724. Acesso em: 18 nov. 2024.
APA
Melo, M. A. de, Macedo, B. G. S., Fonseca, N. P., Scheucher, P. S., Martins, D. A. P., Traina, F., & Machado Neto, J. A. (2023). Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors. Blood, 142( Supl. 1), 5752. doi:10.1182/blood-2023-190724
NLM
Melo MA de, Macedo BGS, Fonseca NP, Scheucher PS, Martins DAP, Traina F, Machado Neto JA. Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors [Internet]. Blood. 2023 ; 142( Supl. 1): 5752.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1182/blood-2023-190724
Vancouver
Melo MA de, Macedo BGS, Fonseca NP, Scheucher PS, Martins DAP, Traina F, Machado Neto JA. Autophagy induction constitutes a targetable vulnerability in FLT3-mutant acute Myeloid Leukemia cells treated with FLT3-inhibitors [Internet]. Blood. 2023 ; 142( Supl. 1): 5752.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1182/blood-2023-190724
Artigo de periodico
NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells (2022)
Miranda, Lívia Bassani Lins De ; Lima, Keli Cristina de ; Silva, Juan Luiz Coelho ; Traina, Fabiola ; Kobayashi, Susumu S. ; Machado Neto, João Agostinho
Source: Scientific Reports. Unidades: FMRP, ICB, FM
Subjects: FARMACOLOGIA, NEOPLASIAS PULMONARES, ANTINEOPLÁSICOS, NEOPLASIAS PULMONARES, ANTINEOPLÁSICOS, CÉLULAS CULTIVADAS DE TUMOR, ONCOGENES, TRANSDUÇÃO DE SINAL CELULAR, PROTEÍNAS PROTO-ONCOGÊNICAS, PROTEÍNAS QUINASES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MIRANDA, Lívia Bassani Lins De et al. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells. Scientific Reports, v. 12, p. 1-11, 2022Tradução . . Disponível em: https://doi.org/10.1038/s41598-022-21419-6. Acesso em: 18 nov. 2024.
APA
Miranda, L. B. L. D., Lima, K. C. de, Silva, J. L. C., Traina, F., Kobayashi, S. S., & Machado Neto, J. A. (2022). NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells. Scientific Reports, 12, 1-11. doi:10.1038/s41598-022-21419-6
NLM
Miranda LBLD, Lima KC de, Silva JLC, Traina F, Kobayashi SS, Machado Neto JA. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells [Internet]. Scientific Reports. 2022 ; 12 1-11.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1038/s41598-022-21419-6
Vancouver
Miranda LBLD, Lima KC de, Silva JLC, Traina F, Kobayashi SS, Machado Neto JA. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells [Internet]. Scientific Reports. 2022 ; 12 1-11.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1038/s41598-022-21419-6
Artigo de periodico
Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms (2022)
Costa, Amanda Fernandes de Oliveira ; Marani, Leticia Olops ; Bianco, Thiago Mantello ; Arantes, Adriana Queiroz; Lopes, Izabela Aparecida; Martins, Diego Antonio Pereira; Palma, Leonardo Carvalho ; Scheucher, Priscila Santos ; Schiavinato, Josiane Lilian dos Santos ; Silva, Cleide Lucia Araújo ; Kobayashi, Susumu S. ; Machado Neto, João Agostinho ; Rego, Eduardo Magalhães ; Welner, Robert Samuel; Pontes, Lorena Lobo de Figueiredo
Source: Frontiers in Immunology. Unidades: FMRP, ICB, FM
Subjects: FARMACOLOGIA, MUTAÇÃO, CITOMETRIA DE FLUXO, CÉLULAS CULTIVADAS DE TUMOR, CÉLULAS DA MEDULA ÓSSEA, LEUCEMIA, CÉLULAS SANGUÍNEAS, MEDULA ÓSSEA, CÉLULAS-TRONCO, LINFÓCITOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
COSTA, Amanda Fernandes de Oliveira et al. Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms. Frontiers in Immunology, v. 13, p. 1-15, 2022Tradução . . Disponível em: https://doi.org/10.3389/fimmu.2022.768592. Acesso em: 18 nov. 2024.
APA
Costa, A. F. de O., Marani, L. O., Bianco, T. M., Arantes, A. Q., Lopes, I. A., Martins, D. A. P., et al. (2022). Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms. Frontiers in Immunology, 13, 1-15. doi:10.3389/fimmu.2022.768592
NLM
Costa AF de O, Marani LO, Bianco TM, Arantes AQ, Lopes IA, Martins DAP, Palma LC, Scheucher PS, Schiavinato JL dos S, Silva CLA, Kobayashi SS, Machado Neto JA, Rego EM, Welner RS, Pontes LL de F. Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms [Internet]. Frontiers in Immunology. 2022 ; 13 1-15.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3389/fimmu.2022.768592
Vancouver
Costa AF de O, Marani LO, Bianco TM, Arantes AQ, Lopes IA, Martins DAP, Palma LC, Scheucher PS, Schiavinato JL dos S, Silva CLA, Kobayashi SS, Machado Neto JA, Rego EM, Welner RS, Pontes LL de F. Altered distribution and function of NK-cell subsets lead to impaired tumor surveillance in JAK2V617F myeloproliferative neoplasms [Internet]. Frontiers in Immunology. 2022 ; 13 1-15.[citado 2024 nov. 18 ] Available from: https://doi.org/10.3389/fimmu.2022.768592
Artigo de periodico
Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells (2022)
Fernandes, Jaqueline Cristina; Fenerich, Bruna Alves ; Silva, Antônio Bruno Alves; Fonseca, Natasha Peixoto ; Silva, Juan Luiz Coelho ; Scheucher, Priscila Santos ; Rego, Eduardo Magalhães ; Pontes, Lorena Lôbo Figueiredo ; Machado Neto, João Agostinho ; Traina, Fabiola
Source: Toxicology in Vitro. Unidades: FM, FMRP, ICB
Subjects: FARMACOLOGIA, ANTINEOPLÁSICOS, INIBIDORES QUÍMICOS, MEDULA ÓSSEA, CÉLULAS-TRONCO, PROLIFERAÇÃO CELULAR, APOPTOSE, MUTAÇÃO, CÉLULAS MIELOIDES, FATORES DE CRESCIMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FERNANDES, Jaqueline Cristina et al. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. Toxicology in Vitro, v. 83, p. 1-7, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.tiv.2022.105384. Acesso em: 18 nov. 2024.
APA
Fernandes, J. C., Fenerich, B. A., Silva, A. B. A., Fonseca, N. P., Silva, J. L. C., Scheucher, P. S., et al. (2022). Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells. Toxicology in Vitro, 83, 1-7. doi:10.1016/j.tiv.2022.105384
NLM
Fernandes JC, Fenerich BA, Silva ABA, Fonseca NP, Silva JLC, Scheucher PS, Rego EM, Pontes LLF, Machado Neto JA, Traina F. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells [Internet]. Toxicology in Vitro. 2022 ; 83 1-7.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.tiv.2022.105384
Vancouver
Fernandes JC, Fenerich BA, Silva ABA, Fonseca NP, Silva JLC, Scheucher PS, Rego EM, Pontes LLF, Machado Neto JA, Traina F. Differential cytotoxic activity of pharmacological inhibitors of IGF1R-related pathways in JAK2V617F driven cells [Internet]. Toxicology in Vitro. 2022 ; 83 1-7.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.tiv.2022.105384
Artigo de periodico-carta/editorial
Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax (2022)
Lima, Keli Cristina de ; Vicari, Hugo Passos ; Carlos, Jorge Antonio Elias Godoy; Silva, Jean Carlos Lipreri da ; Pontes, Lorena Lobo de Figueiredo ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho
Source: Hematology, Transfusion and Cell Therapy. Unidades: FMRP, FM, ICB
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, APOPTOSE, MEDICAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli Cristina de et al. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2021.01.004. Acesso em: 18 nov. 2024. , 2022
APA
Lima, K. C. de, Vicari, H. P., Carlos, J. A. E. G., Silva, J. C. L. da, Pontes, L. L. de F., Rego, E. M., & Machado Neto, J. A. (2022). Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1016/j.htct.2021.01.004
NLM
Lima KC de, Vicari HP, Carlos JAEG, Silva JCL da, Pontes LL de F, Rego EM, Machado Neto JA. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44( 1): 124-127.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.htct.2021.01.004
Vancouver
Lima KC de, Vicari HP, Carlos JAEG, Silva JCL da, Pontes LL de F, Rego EM, Machado Neto JA. Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax [Internet]. Hematology, Transfusion and Cell Therapy. 2022 ; 44( 1): 124-127.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.htct.2021.01.004
Artigo de periodico
Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms (2022)
Takei, Hisashi; Silva, Juan Luiz Coelho ; Leal, Cristina Tavares; Rocha, Adriana Queiroz Arantes; Bianco, Thiago Mantello ; Welner, Robert S.; Mishima, Yuta ; Kobayashi, Ikei S.; Mullally, Ann ; Lima, Keli Cristina de ; Machado Neto, João Agostinho ; Kobayashi, Susumu S. ; Pontes, Lorena Lobo De Figueiredo
Source: Cancer Science. Unidades: ICB, FMRP, FM
Subjects: FARMACOLOGIA, PROTEÍNAS PROTO-ONCOGÊNICAS, INIBIDORES DE ENZIMAS, MODELOS ANIMAIS DE DOENÇAS, FÁRMACOS, MEDICAMENTO, NEOPLASIAS, PROLIFERAÇÃO CELULAR, SOBREVIVÊNCIA CELULAR, CAMUNDONGOS, MUTAÇÃO, APOPTOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TAKEI, Hisashi et al. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Science, v. 113, n. 2, p. 1-12, 2022Tradução . . Disponível em: https://doi.org/10.1111/cas.15210. Acesso em: 18 nov. 2024.
APA
Takei, H., Silva, J. L. C., Leal, C. T., Rocha, A. Q. A., Bianco, T. M., Welner, R. S., et al. (2022). Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms. Cancer Science, 113( 2), 1-12. doi:10.1111/cas.15210
NLM
Takei H, Silva JLC, Leal CT, Rocha AQA, Bianco TM, Welner RS, Mishima Y, Kobayashi IS, Mullally A, Lima KC de, Machado Neto JA, Kobayashi SS, Pontes LLDF. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms [Internet]. Cancer Science. 2022 ; 113( 2): 1-12.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1111/cas.15210
Vancouver
Takei H, Silva JLC, Leal CT, Rocha AQA, Bianco TM, Welner RS, Mishima Y, Kobayashi IS, Mullally A, Lima KC de, Machado Neto JA, Kobayashi SS, Pontes LLDF. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms [Internet]. Cancer Science. 2022 ; 113( 2): 1-12.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1111/cas.15210
Artigo de periodico
Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model (2022)
Silva, Antônio Bruno Alves; Fenerich, Bruna Alves ; Fonseca, Natasha Peixoto ; Fernandes, Jaqueline Cristina; Silva, Juan Luiz Coelho da ; Martins, Diego Antonio Pereira ; Bianco, Thiago Mantello ; Scheucher, Priscila Santos ; Rego, Eduardo Magalhães ; Chahud, Fernando ; Machado Neto, João Agostinho ; Pontes, Lorena Lôbo de Figueiredo ; Traina, Fabiola
Source: Investigational New Drugs. Unidades: FMRP, FM, ICB
Subjects: FARMACOLOGIA, CÉLULAS CULTIVADAS DE TUMOR, ANTIDIABÉTICOS (HIPOGLICEMIANTES), HEMATOPOESE, CÉLULAS SANGUÍNEAS, CÉLULAS-TRONCO, DOENÇAS HEMATOLÓGICAS, POLICITEMIA, PLAQUETAS SANGUÍNEAS, ANTINEOPLÁSICOS, CAMUNDONGOS, MODELOS ANIMAIS DE DOENÇAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Antônio Bruno Alves et al. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Investigational New Drugs, p. 1-10, 2022Tradução . . Disponível em: https://doi.org/10.1007/s10637-022-01212-y. Acesso em: 18 nov. 2024.
APA
Silva, A. B. A., Fenerich, B. A., Fonseca, N. P., Fernandes, J. C., Silva, J. L. C. da, Martins, D. A. P., et al. (2022). Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model. Investigational New Drugs, 1-10. doi:10.1007/s10637-022-01212-y
NLM
Silva ABA, Fenerich BA, Fonseca NP, Fernandes JC, Silva JLC da, Martins DAP, Bianco TM, Scheucher PS, Rego EM, Chahud F, Machado Neto JA, Pontes LL de F, Traina F. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model [Internet]. Investigational New Drugs. 2022 ; 1-10.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s10637-022-01212-y
Vancouver
Silva ABA, Fenerich BA, Fonseca NP, Fernandes JC, Silva JLC da, Martins DAP, Bianco TM, Scheucher PS, Rego EM, Chahud F, Machado Neto JA, Pontes LL de F, Traina F. Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model [Internet]. Investigational New Drugs. 2022 ; 1-10.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s10637-022-01212-y
Artigo de periodico
Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia (2021)
Silva, Jean Carlos Lipreri da ; Silva, Juan Luiz Coelho ; Lima, Keli ; Vicari, Hugo Passos ; Lazarini, Mariana ; Costa-Lotufo, Letícia Veras ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: Cellular Oncology. Unidades: ICB, FMRP
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE AGUDA, ANTINEOPLÁSICOS, CITOESQUELETO, EXPRESSÃO GÊNICA, GENÔMICA, TRANSDUÇÃO DE SINAL CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Jean Carlos Lipreri da et al. Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia. Cellular Oncology, v. 44, n. 5, p. 1105-1117, 2021Tradução . . Disponível em: https://doi.org/10.1007/s13402-021-00621-0. Acesso em: 18 nov. 2024.
APA
Silva, J. C. L. da, Silva, J. L. C., Lima, K., Vicari, H. P., Lazarini, M., Costa-Lotufo, L. V., et al. (2021). Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia. Cellular Oncology, 44( 5), 1105-1117. doi:10.1007/s13402-021-00621-0
NLM
Silva JCL da, Silva JLC, Lima K, Vicari HP, Lazarini M, Costa-Lotufo LV, Traina F, Machado Neto JA. Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia [Internet]. Cellular Oncology. 2021 ; 44( 5): 1105-1117.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s13402-021-00621-0
Vancouver
Silva JCL da, Silva JLC, Lima K, Vicari HP, Lazarini M, Costa-Lotufo LV, Traina F, Machado Neto JA. Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia [Internet]. Cellular Oncology. 2021 ; 44( 5): 1105-1117.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s13402-021-00621-0
Artigo de periodico
Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome (2021)
Silva, Juan Luiz Coelho ; Silveira, Douglas Rafaele Almeida ; Martins, Diego Antonio Pereira ; Rojas, Cesar A. O.; Araujo, Antonio R. Lucena ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho ; Bendit, Israel ; Rocha, Vanderson Geraldo ; Traina, Fabiola
Source: Scientific Reports. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, FARMACOGENÉTICA, EXPRESSÃO GÊNICA, CICLO CELULAR, MEDULA ÓSSEA, DOENÇAS SANGUÍNEAS E LINFÁTICAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Juan Luiz Coelho et al. Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. Scientific Reports, v. 11, p. 11 , 2021Tradução . . Disponível em: https://doi.org/10.1038/s41598-020-80918-6. Acesso em: 18 nov. 2024.
APA
Silva, J. L. C., Silveira, D. R. A., Martins, D. A. P., Rojas, C. A. O., Araujo, A. R. L., Rego, E. M., et al. (2021). Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome. Scientific Reports, 11, 11 . doi:10.1038/s41598-020-80918-6
NLM
Silva JLC, Silveira DRA, Martins DAP, Rojas CAO, Araujo ARL, Rego EM, Machado Neto JA, Bendit I, Rocha VG, Traina F. Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome [Internet]. Scientific Reports. 2021 ; 11 11 .[citado 2024 nov. 18 ] Available from: https://doi.org/10.1038/s41598-020-80918-6
Vancouver
Silva JLC, Silveira DRA, Martins DAP, Rojas CAO, Araujo ARL, Rego EM, Machado Neto JA, Bendit I, Rocha VG, Traina F. Molecular-based score inspired on metabolic signature improves prognostic stratification for myelodysplastic syndrome [Internet]. Scientific Reports. 2021 ; 11 11 .[citado 2024 nov. 18 ] Available from: https://doi.org/10.1038/s41598-020-80918-6
Artigo de periodico
STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells (2021)
Vicari, Hugo Passos ; Silva, Juan Luiz Coelho da ; Martins, Diego Antonio Pereira ; Araujo, Antônio Roberto Lucena de ; Lima, Keli Cristina de ; Silva, Jean Carlos Lipreri da ; Scheucher, Priscila Santos ; Koury, Luisa C.; Melo, Raul A. de ; Bittencourt, Rosane; Pagnano, Katia ; Nunes, Elenaide ; Fagundes, Evandro Maranhão ; Kerbauy, Fabio; Pontes, Lorena Lobo de Figueiredo ; Costa-Lotufo, Letícia Veras ; Rego, Eduardo Magalhães ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: Investigational New Drugs. Unidades: FMRP, ICB, FM
Subjects: FARMACOLOGIA, CÉLULAS SANGUÍNEAS, CLONAGEM, LEUCEMIA MIELOIDE AGUDA, ONCOPROTEÍNAS, CÉLULAS MIELOIDES, CICLO CELULAR, HEMATOPOESE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VICARI, Hugo Passos et al. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, p. 1-15, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-021-01197-0. Acesso em: 18 nov. 2024.
APA
Vicari, H. P., Silva, J. L. C. da, Martins, D. A. P., Araujo, A. R. L. de, Lima, K. C. de, Silva, J. C. L. da, et al. (2021). STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells. Investigational New Drugs, 1-15. doi:10.1007/s10637-021-01197-0
NLM
Vicari HP, Silva JLC da, Martins DAP, Araujo ARL de, Lima KC de, Silva JCL da, Scheucher PS, Koury LC, Melo RA de, Bittencourt R, Pagnano K, Nunes E, Fagundes EM, Kerbauy F, Pontes LL de F, Costa-Lotufo LV, Rego EM, Traina F, Machado Neto JA. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells [Internet]. Investigational New Drugs. 2021 ; 1-15.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s10637-021-01197-0
Vancouver
Vicari HP, Silva JLC da, Martins DAP, Araujo ARL de, Lima KC de, Silva JCL da, Scheucher PS, Koury LC, Melo RA de, Bittencourt R, Pagnano K, Nunes E, Fagundes EM, Kerbauy F, Pontes LL de F, Costa-Lotufo LV, Rego EM, Traina F, Machado Neto JA. STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells [Internet]. Investigational New Drugs. 2021 ; 1-15.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s10637-021-01197-0
Artigo de periodico
NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia (2021)
Ribeiro, Renata Scopim ; Machado Neto, João Agostinho ; Eide, Christopher A. ; Silva, Juan Luiz Coelho da ; Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Scheucher, Priscila Santos ; Stevens, Samantha L. Savage ; Campos, Paula de Melo; Saad, Sara T. Olalla ; Palma, Leonardo de Carvalho ; Pontes, Lorena Lobo de Figueiredo ; Simões, Belinda Pinto ; Rego, Eduardo Magalhães ; Tognon, Cristina E. ; Druker, Brian J. ; Traina, Fabiola
Source: Investigational New Drugs. Unidades: ICB, FMRP, FM
Subjects: FARMACOLOGIA, LEUCEMIA MIELOIDE, INSULINA, ANTINEOPLÁSICOS, PROTEÍNAS QUINASES, CÉLULAS SANGUÍNEAS, PROLIFERAÇÃO CELULAR, APOPTOSE, ONCOGENES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIBEIRO, Renata Scopim et al. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, v. 39, n. 3, p. 736-746, 2021Tradução . . Disponível em: https://doi.org/10.1007/s10637-020-01028-8. Acesso em: 18 nov. 2024.
APA
Ribeiro, R. S., Machado Neto, J. A., Eide, C. A., Silva, J. L. C. da, Fenerich, B. A., Fernandes, J. C., et al. (2021). NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia. Investigational New Drugs, 39( 3), 736-746. doi:10.1007/s10637-020-01028-8
NLM
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Vancouver
Ribeiro RS, Machado Neto JA, Eide CA, Silva JLC da, Fenerich BA, Fernandes JC, Scheucher PS, Stevens SLS, Campos P de M, Saad STO, Palma L de C, Pontes LL de F, Simões BP, Rego EM, Tognon CE, Druker BJ, Traina F. NT157, an IGF1R-IRS1/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia [Internet]. Investigational New Drugs. 2021 ; 39( 3): 736-746.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s10637-020-01028-8
Artigo de periodico
Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells (2020)
Machado Neto, João Agostinho ; Silva, Juan Luiz Coelho da ; Santos, Fábio Pires de Souza ; Scheucher, Priscila Santos ; Campregher, Paulo Vidal ; Hamerschlak, Nelson ; Rego, Eduardo Magalhães ; Traina, Fabiola
Source: Investigational New Drugs. Unidades: ICB, FMRP
Subjects: FARMACOLOGIA, APOPTOSE, LEUCEMIA MIELOIDE AGUDA, NEOPLASIAS POR TIPO HISTOLÓGICO, ANTIMALÁRICOS, CÉLULAS MIELOIDES, CÉLULAS SANGUÍNEAS, ERITRÓCITOS, MUTAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MACHADO NETO, João Agostinho et al. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. Investigational New Drugs, v. 38, p. 733–745, 2020Tradução . . Disponível em: https://doi.org/10.1007/s10637-019-00812-5. Acesso em: 18 nov. 2024.
APA
Machado Neto, J. A., Silva, J. L. C. da, Santos, F. P. de S., Scheucher, P. S., Campregher, P. V., Hamerschlak, N., et al. (2020). Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells. Investigational New Drugs, 38, 733–745. doi:10.1007/s10637-019-00812-5
NLM
Machado Neto JA, Silva JLC da, Santos FP de S, Scheucher PS, Campregher PV, Hamerschlak N, Rego EM, Traina F. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells [Internet]. Investigational New Drugs. 2020 ; 38 733–745.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s10637-019-00812-5
Vancouver
Machado Neto JA, Silva JLC da, Santos FP de S, Scheucher PS, Campregher PV, Hamerschlak N, Rego EM, Traina F. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2V617F cells [Internet]. Investigational New Drugs. 2020 ; 38 733–745.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s10637-019-00812-5
Artigo de periodico
Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms (2020)
Soares, Moysés Antonio Porto ; Oliveira, Rafael Daltro de; Cortopassi, Gabriel Macedo ; Machado Neto, João Agostinho ; Palma, L. C.; Pontes, Lorena Lôbo de Figueiredo
Source: Hematology, Transfusion and Cell Therapy. Unidades: ICB, FMRP, EP
Subjects: FARMACOLOGIA, ESTUDOS DE COORTES, PACIENTES, DOENÇAS DA MEDULA ÓSSEA, NEOPLASIAS ÓSSEAS, MUTAÇÃO GENÉTICA, POLICITEMIA, TROMBOCITOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOARES, Moysés Antonio Porto et al. Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms. Hematology, Transfusion and Cell Therapy, v. 42, n. 3, p. 238-244, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.htct.2019.07.008. Acesso em: 18 nov. 2024.
APA
Soares, M. A. P., Oliveira, R. D. de, Cortopassi, G. M., Machado Neto, J. A., Palma, L. C., & Pontes, L. L. de F. (2020). Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms. Hematology, Transfusion and Cell Therapy, 42( 3), 238-244. doi:10.1016/j.htct.2019.07.008
NLM
Soares MAP, Oliveira RD de, Cortopassi GM, Machado Neto JA, Palma LC, Pontes LL de F. Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms [Internet]. Hematology, Transfusion and Cell Therapy. 2020 ; 42( 3): 238-244.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.htct.2019.07.008
Vancouver
Soares MAP, Oliveira RD de, Cortopassi GM, Machado Neto JA, Palma LC, Pontes LL de F. Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms [Internet]. Hematology, Transfusion and Cell Therapy. 2020 ; 42( 3): 238-244.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.htct.2019.07.008
Artigo de periodico
Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia (2020)
Carlos, Jorge Antonio Elias Godoy; Lima, Keli ; Silva, Juan Luiz Coelho da ; Paiva, Raquel de Melo Alves ; Moreno, Natália Cestari ; Vicari, Hugo Passos ; Santos, Fábio Pires de Souza ; Hamerschlak, Nelson ; Traina, Fabiola ; Costa-Lotufo, Letícia Veras ; Machado Neto, João Agostinho
Source: Cellular Oncology (Dordrecht, 2011). Unidades: FMRP, ICB, IQ, FM
Subjects: FARMACOLOGIA, APOPTOSE, LEUCEMIA MIELOIDE AGUDA, MITOSE, NEOPLASIAS, PURINAS, EXPRESSÃO GÊNICA, LINFÓCITOS, PROLIFERAÇÃO CELULAR, DANO AO DNA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CARLOS, Jorge Antonio Elias Godoy et al. Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia. Cellular Oncology (Dordrecht, 2011), v. 43, n. 6, p. 1191-1201, 2020Tradução . . Disponível em: https://doi.org/10.1007/s13402-020-00551-3. Acesso em: 18 nov. 2024.
APA
Carlos, J. A. E. G., Lima, K., Silva, J. L. C. da, Paiva, R. de M. A., Moreno, N. C., Vicari, H. P., et al. (2020). Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia. Cellular Oncology (Dordrecht, 2011), 43( 6), 1191-1201. doi:10.1007/s13402-020-00551-3
NLM
Carlos JAEG, Lima K, Silva JLC da, Paiva R de MA, Moreno NC, Vicari HP, Santos FP de S, Hamerschlak N, Traina F, Costa-Lotufo LV, Machado Neto JA. Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia [Internet]. Cellular Oncology (Dordrecht, 2011). 2020 ; 43( 6): 1191-1201.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s13402-020-00551-3
Vancouver
Carlos JAEG, Lima K, Silva JLC da, Paiva R de MA, Moreno NC, Vicari HP, Santos FP de S, Hamerschlak N, Traina F, Costa-Lotufo LV, Machado Neto JA. Reversine exerts cytotoxic effects through multiple cell death mechanisms in acute lymphoblastic leukemia [Internet]. Cellular Oncology (Dordrecht, 2011). 2020 ; 43( 6): 1191-1201.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1007/s13402-020-00551-3
Artigo de periodico
NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells (2020)
Fenerich, Bruna Alves ; Fernandes, Jaqueline Cristina; Alves, Ana Paula Nunes Rodrigues; Silva, Juan Luiz Coelho da ; Ribeiro, Renata Scopim; Scheucher, Priscila Santos ; Eide, Christopher A.; Tognon, Cristina E.; Druker, Brian J. ; Rego, Eduardo Magalhães ; Machado Neto, João Agostinho ; Traina, Fabiola
Source: Signal Transduction and Targeted Therapy. Unidades: FMRP, FM, ICB
Subjects: FARMACOLOGIA, TRANSDUÇÃO DE SINAL CELULAR, CÉLULAS CULTIVADAS DE TUMOR, ANTINEOPLÁSICOS, PROLIFERAÇÃO CELULAR, ERITROPOIETINA, APOPTOSE, MUTAÇÃO GENÉTICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FENERICH, Bruna Alves et al. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, p. 10 , 2020Tradução . . Disponível em: https://doi.org/10.1038/s41392-019-0102-5. Acesso em: 18 nov. 2024.
APA
Fenerich, B. A., Fernandes, J. C., Alves, A. P. N. R., Silva, J. L. C. da, Ribeiro, R. S., Scheucher, P. S., et al. (2020). NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction and Targeted Therapy, 10 . doi:10.1038/s41392-019-0102-5
NLM
Fenerich BA, Fernandes JC, Alves APNR, Silva JLC da, Ribeiro RS, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells [Internet]. Signal Transduction and Targeted Therapy. 2020 ; 10 .[citado 2024 nov. 18 ] Available from: https://doi.org/10.1038/s41392-019-0102-5
Vancouver
Fenerich BA, Fernandes JC, Alves APNR, Silva JLC da, Ribeiro RS, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado Neto JA, Traina F. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2V617F-positive myeloproliferative neoplasm cells [Internet]. Signal Transduction and Targeted Therapy. 2020 ; 10 .[citado 2024 nov. 18 ] Available from: https://doi.org/10.1038/s41392-019-0102-5
Trabalho de evento-resumo periodico
Inibição farmacológica de ezrina reduz a viabilidade, a clonogenicidade e a ativação da via PI3K/AKT/mTOR em modelos celulares de leucemia mieloide aguda (2020)
Silva, J. C. L.; Coelho-Silva, J. L.; Lima, K.; Vicari, Hugo Passos ; Costa-Lotufo, Letícia Veras ; Traina, Fabiola; Machado Neto, João Agostinho
Source: Hematology, Transfusion and Cell Therapy. Conference titles: Congresso Brasileiro de Hematologia, Hemoterapia e Terapia Celular - HemoPlay. Unidades: ICB, FMRP
Subjects: LEUCEMIA MIELOIDE AGUDA, HEMATOLOGIA, GENES, FARMACOLOGIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, J. C. L. et al. Inibição farmacológica de ezrina reduz a viabilidade, a clonogenicidade e a ativação da via PI3K/AKT/mTOR em modelos celulares de leucemia mieloide aguda. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Instituto de Ciências Biomédicas, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.htct.2020.10.267. Acesso em: 18 nov. 2024. , 2020
APA
Silva, J. C. L., Coelho-Silva, J. L., Lima, K., Vicari, H. P., Costa-Lotufo, L. V., Traina, F., & Machado Neto, J. A. (2020). Inibição farmacológica de ezrina reduz a viabilidade, a clonogenicidade e a ativação da via PI3K/AKT/mTOR em modelos celulares de leucemia mieloide aguda. Hematology, Transfusion and Cell Therapy. São José do Rio Preto: Instituto de Ciências Biomédicas, Universidade de São Paulo. doi:10.1016/j.htct.2020.10.267
NLM
Silva JCL, Coelho-Silva JL, Lima K, Vicari HP, Costa-Lotufo LV, Traina F, Machado Neto JA. Inibição farmacológica de ezrina reduz a viabilidade, a clonogenicidade e a ativação da via PI3K/AKT/mTOR em modelos celulares de leucemia mieloide aguda [Internet]. Hematology, Transfusion and Cell Therapy. 2020 ; 42 S158-S159.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.htct.2020.10.267
Vancouver
Silva JCL, Coelho-Silva JL, Lima K, Vicari HP, Costa-Lotufo LV, Traina F, Machado Neto JA. Inibição farmacológica de ezrina reduz a viabilidade, a clonogenicidade e a ativação da via PI3K/AKT/mTOR em modelos celulares de leucemia mieloide aguda [Internet]. Hematology, Transfusion and Cell Therapy. 2020 ; 42 S158-S159.[citado 2024 nov. 18 ] Available from: https://doi.org/10.1016/j.htct.2020.10.267
Artigo de periodico
Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms (2019)
Lima, Keli Cristina de ; Carlos, Jorge Antonio Elias Godoy; Paiva, Raquel de Melo Alves ; Vicari, Hugo Passos; Santos, Fábio Pires de Souza ; Hamerschlak, Nelson ; Costa-Lotufo, Letícia Veras ; Traina, Fabiola ; Machado Neto, João Agostinho
Source: Scientific Reports. Unidades: ICB, FMRP
Subjects: FARMACOLOGIA, DOENÇAS DA MEDULA ÓSSEA, TRANSTORNOS MIELOPROLIFERATIVOS, ANTINEOPLÁSICOS, EXPRESSÃO GÊNICA, CITOESQUELETO, DANO AO DNA, PROLIFERAÇÃO CELULAR, APOPTOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LIMA, Keli Cristina de et al. Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms. Scientific Reports, v. 9, p. 9 , 2019Tradução . . Disponível em: https://doi.org/10.1038/s41598-019-46163-2. Acesso em: 18 nov. 2024.
APA
Lima, K. C. de, Carlos, J. A. E. G., Paiva, R. de M. A., Vicari, H. P., Santos, F. P. de S., Hamerschlak, N., et al. (2019). Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms. Scientific Reports, 9, 9 . doi:10.1038/s41598-019-46163-2
NLM
Lima KC de, Carlos JAEG, Paiva R de MA, Vicari HP, Santos FP de S, Hamerschlak N, Costa-Lotufo LV, Traina F, Machado Neto JA. Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms [Internet]. Scientific Reports. 2019 ; 9 9 .[citado 2024 nov. 18 ] Available from: https://doi.org/10.1038/s41598-019-46163-2
Vancouver
Lima KC de, Carlos JAEG, Paiva R de MA, Vicari HP, Santos FP de S, Hamerschlak N, Costa-Lotufo LV, Traina F, Machado Neto JA. Reversine exhibits antineoplastic activity in JAK2V617F-positive myeloproliferative neoplasms [Internet]. Scientific Reports. 2019 ; 9 9 .[citado 2024 nov. 18 ] Available from: https://doi.org/10.1038/s41598-019-46163-2

USP Schools

ReP

Filtros

Authors

USP affiliated authors

Date published

Subjects

Source title

Countries/Territories

Funding Agencies

Non normalized affiliation